Sarepta Therapeutics (SRPT) Revenue (2012 - 2026)

Sarepta Therapeutics' Revenue history runs 13 years deep, the most recent figure standing at $400.3 million for Q1 2026.

• In Q1 2026, Revenue rose 200.22% year-over-year to $400.3 million; the TTM figure through Mar 2026 stood at $1.9 billion (up 14.29% YoY), while the FY2025 annual figure was $2.2 billion, up 15.58% from the prior year.
• Revenue was $400.3 million for Q1 2026 at Sarepta Therapeutics, down from $442.9 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $658.4 million in Q4 2024 to a low of $22.0 million in Q1 2022.
• Historically, Revenue has averaged $327.7 million across 5 years, with a median of $362.9 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Revenue slumped 89.46% in 2023, then soared 1531.15% in 2024.
• A 5-year view of Revenue shows it stood at $169.2 million in 2022, then surged by 173.98% to $463.5 million in 2023, then jumped by 42.04% to $658.4 million in 2024, then sank by 32.73% to $442.9 million in 2025, then slipped by 9.63% to $400.3 million in 2026.
• The last three Revenue figures came in at $400.3 million (Q1 2026), $442.9 million (Q4 2025), and $399.4 million (Q3 2025), per Business Quant data.